Dr. Frank L. Douglas is an award-winning industry veteran with more than three decades of experience in healthcare, pharmaceuticals, and entrepreneurship. He has held senior roles in both large and small biopharmaceutical companies, including Executive Vice President and Board Member at Aventis (now Sanofi), where he oversaw global R&D and regulatory affairs. He played a key role in the development of drugs like Allegra, Lantus, Taxotere, and Actonel. He also served as Chief Scientific Advisor at Bayer and chaired Alantos, later acquired by Amgen.